PT-141 typical research dosing
Across the available literature, PT-141 is most commonly administered at 1000–2000 mcg per dose, 1 time(s) per day, via subcutaneous injection. PT-141 is used on an as-needed basis, not daily. The FDA-approved Vyleesi dose is 1.75 mg (1750 mcg) subcutaneously 45 minutes before anticipated sexual activity, no more than once per 24 hours and no more than once per 8 days. Research protocols have studied 1–2 mg.
PT-141 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 10 mg PT-141 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 1000 mcg | 1500 mcg | 2000 mcg |
|---|---|---|---|---|
| 1 mL | 10000 mcg/mL | 10.0 units | 15.0 units | 20.0 units |
| 2 mL | 5000 mcg/mL | 20.0 units | 30.0 units | 40.0 units |
| 3 mL | 3333 mcg/mL | 30.0 units | 45.0 units | 60.0 units |
| 5 mL | 2000 mcg/mL | 50.0 units | 75.0 units | 100.0 units |
PT-141 cycle length
PT-141 is typically used continuously rather than cycled in research protocols.
PT-141 half-life and timing
PT-141 has a half-life of approximately 2.7 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.